8-K: QHSLab, Inc. Reports Record Revenue Growth and Positive Net Income in Preliminary Q4 and FY 2024 Financial Results

QHSLab, Inc. announces record revenue growth and its first profitable year in 2024, driven by a 98% revenue surge in Q4 compared to the previous year.

Summary

• QHSLab, Inc. reported preliminary unaudited financial results for Q4 and the full year 2024.
• The company achieved record revenue growth and its first profitable year.
• Q4 2024 revenue increased by 98% year-over-year to $625,981, compared to $315,020 in Q4 2023.
• Gross profit for Q4 2024 increased by 117% to $412,154, with gross margin expanding to 65.8% from 60.3% in the prior-year quarter.
• Net income for Q4 2024 was $40,838, a significant improvement from a net loss of $86,627 in Q4 2023.
• Full-year 2024 revenue grew by 51% year-over-year, reaching $2.1 million compared to $1.4 million for the full-year 2023.
• Gross margin for the full year improved to 63.7%.
• The company recorded net income of $69,188 for 2024, compared to a net loss of $468,362 in 2023.
• The company reported net positive cash flow of $105,586, driven by $247,317 in cash flow from operations.
• The company repaid $298,531 in loans, further strengthening its balance sheet.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with record revenue growth, profitability, and debt reduction, indicating strong financial performance and future potential.

Positives

• Record revenue growth was achieved in 2024.
• The company achieved its first profitable year.
• Revenue surged 98% in Q4 2024 compared to Q4 2023.
• Full-year 2024 revenue grew 51% year-over-year.
• Gross margin improved to 63.7% for the full year.
• The company generated positive cash flow of $105,586.
• The company repaid $298,531 in loans, strengthening its balance sheet.

Risks

• The financial results are preliminary and unaudited, subject to change upon completion of the independent year-end audit.
• The company's forward-looking statements are subject to numerous risks and uncertainties, including regulatory delays and changes in government funding.

Future Outlook

Management is confident in the reported numbers and expects only minor adjustments, if any, upon completion of the audit. The company anticipates continued strong financial performance and value to shareholders in 2025.

Management Comments

• These outstanding financial results reflect the continued execution of our strategic initiatives and the growing adoption of our digital medicine solutions, said Troy Grogan, President and CEO of QHSLab.
• As we increase the number of physicians using QHSLab, our financial performance should continue to improve.
• We look forward to sharing our fully audited results in the coming weeks and remain committed to delivering strong financial performance and value to our shareholders, added Troy Grogan.
• With our continued expansion and operational efficiencies, we are excited about the future of QHSLab as we build on this momentum into 2025.

Industry Context

The announcement highlights the growing adoption of digital medicine solutions and point-of-care diagnostics in primary care, reflecting a broader trend in the healthcare industry towards personalized and remote patient monitoring.

Comparison to Industry Standards

• It is difficult to compare QHSLab directly to industry standards without knowing their specific market segment and competitors.
• However, companies like Teladoc Health and Amwell are larger players in the telehealth space, while companies like Abbott and Roche are major players in the diagnostics market.
• QHSLab's growth rates and profitability should be compared to similar-sized companies in the digital health and point-of-care diagnostics sectors to assess its relative performance.

Stakeholder Impact

• Shareholders can expect increased value due to the company's improved financial performance.
• Employees may benefit from increased job security and potential growth opportunities.
• Customers (physicians) can expect continued improvements in the company's digital healthcare solutions and point-of-care diagnostics.

Next Steps

• Finalizing the independent year-end audit.
• Filing the Annual Report on Form 10-K prior to the 2024 SEC reporting deadline.
• Continuing expansion and operational efficiencies into 2025.

Key Dates

Keywords

financial results, revenue growth, net income, digital health, QHSLab, profitability